Company profile: Taligen Therapeutics
1.1 - Company Overview
Company description
- Provider of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases, with lead candidates including monoclonal antibodies and recombinant fusion proteins targeting key factors.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Taligen Therapeutics
Talaris Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology engaged in developing innovative cellular therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Talaris Therapeutics company profile →
PureTech Health
HQ: United States
Website
- Description: Provider of biopharma therapies and platforms, including KarXT for schizophrenia (xanomeline + trospium), LYT-100 (deuterated pirfenidone) for idiopathic pulmonary fibrosis, LYT-200 (anti-galectin-9) for hematological malignancies and solid tumors, SPT-300 (oral allopregnanolone) for neurological and neuropsychiatric conditions, plus Vedanta's microbiome-based oral therapies and Entrega's hydrogel-enabled oral biologics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PureTech Health company profile →
ImmuPharma
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development focused on pioneering, novel therapies in specialist therapeutic areas with few existing treatments. Pipeline includes P140 (Lupuzor) in Phase 3 for SLE, P140 in Phase 2/3 for CIDP, BioAMB (amphotericin-B variant) in preclinical for serious fungal infections, and BioCIN (vancomycin-based) in preclinical for severe bacterial infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmuPharma company profile →
SetPoint Medical
HQ: United States
Website
- Description: Provider of neuroimmune modulation solutions for chronic autoimmune conditions, including a platform that activates immunomodulatory pathways via targeted electrical stimulation to regulate inflammation, and a small vagus nerve stimulation device with integrated circuit, telemetry and rechargeable battery controlled via iPad. Also conducts clinical research, including RESET-RA, a randomized, double-blind rheumatoid arthritis study.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SetPoint Medical company profile →
Genespire
HQ: Italy
Website
- Description: Provider of transformative gene therapies for genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Offers Immune Shielded Lentiviral Vectors for direct liver use enabling long-term hepatocyte-specific expression for one-time treatments, and an Advanced Gene Editing Platform enabling high-efficacy, permanent targeted gene integration in T-cells and HSPCs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genespire company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Taligen Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Taligen Therapeutics
2.2 - Growth funds investing in similar companies to Taligen Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Taligen Therapeutics
4.2 - Public trading comparable groups for Taligen Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →